Stephen F. Betz - Sep 1, 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Scientific Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Sep 1, 2022
Transactions value $
-$43,390
Form type
4
Date filed
9/6/2022, 04:20 PM
Previous filing
May 4, 2022
Next filing
Sep 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Other $14.7K +1.34K +1.24% $11.02 109K May 20, 2022 Direct F1
transaction CRNX Common Stock Sale -$58.1K -3.13K -2.87% $18.59 106K Sep 1, 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).
F2 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.